- Trials with a EudraCT protocol (71)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
71 result(s) found for: Tanner Scale.
Displaying page 1 of 4.
EudraCT Number: 2011-002379-40 | Sponsor Protocol Number: CAFQ056B2278 | Start Date*: 2012-01-09 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: An open-label study to evaluate the long-term safety and tolerability of AFQ056 in adolescent patients with Fragile X Syndrome | |||||||||||||
Medical condition: Fragile X syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended) Outside EU/EEA GB (Prematurely Ended) ES (Temporarily Halted) DK (Prematurely Ended) IT (Completed) FR (Completed) NL (Prematurely Ended) BE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005593-79 | Sponsor Protocol Number: A6391004 | Start Date*: 2006-06-02 | |||||||||||
Sponsor Name:Pfizer Limited | |||||||||||||
Full Title: A Double blind, third party open, single dose study to explore the safety, pharmacokinetics and pharmacodynamics of pha-794428 in paediatric patients with growth hormone deficiency | |||||||||||||
Medical condition: Paediatric Growth Hormone Deficiency | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) ES (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003718-10 | Sponsor Protocol Number: 2014RISP-ID01 | Start Date*: 2015-09-15 |
Sponsor Name:UMCG | ||
Full Title: A placebo-controlled discontinuation trial of off-label used risperidone in people with intellectual disability | ||
Medical condition: no specific condition, we will investigate people with intellectual disability who have been using risperidone on an off-label basis for at least one year. | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-004419-38 | Sponsor Protocol Number: CL3-95008-001 | Start Date*: 2018-10-04 | |||||||||||
Sponsor Name:Institut de Recherches Internationales Servier | |||||||||||||
Full Title: Efficacy and safety of bumetanide oral liquid formulation in children and adolescents aged from 7 to less than 18 years old with Autism Spectrum Disorder. A 6-month randomised, double-blind, place... | |||||||||||||
Medical condition: Autism Spectrum Disorder (ASD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Prematurely Ended) DE (Completed) ES (Prematurely Ended) NL (Completed) HU (Completed) PT (Completed) PL (Prematurely Ended) IT (Completed) IE (Prematurely Ended) CZ (Ongoing) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004915-22 | Sponsor Protocol Number: A3921145 | Start Date*: 2012-08-03 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, New York 10017 | |||||||||||||
Full Title: A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF CP-690,550 FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) | |||||||||||||
Medical condition: JUVENILE IDIOPATHIC ARTHRITIS (JIA) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) PL (Ongoing) DE (Restarted) SK (Completed) IT (Restarted) ES (Ongoing) GB (GB - no longer in EU/EEA) BE (Ongoing) NL (Prematurely Ended) SE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002181-23 | Sponsor Protocol Number: CL3-20098-076 | Start Date*: 2015-12-14 | |||||||||||
Sponsor Name:Institut de Recherche International Servier | |||||||||||||
Full Title: Efficacy and safety of 2 doses of agomelatine (10mg, 25mg) given orally in children (from 7 to less than 12 years) and adolescents (from 12 to less than 18 years) with moderate to severe Major Depr... | |||||||||||||
Medical condition: Major Depressive Disorder | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) HU (Completed) DE (Ongoing) BG (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003120-17 | Sponsor Protocol Number: PDY16963 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Genzyme Corporation | |||||||||||||
Full Title: A 3-part study to evaluate the efficacy and safety of venglustat in combination with Cerezyme in adult and pediatric patients with Gaucher disease Type 3 (GD3) with open-label long-term treatment | |||||||||||||
Medical condition: Gaucher disease type 3 | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended) HU (Prematurely Ended) FR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002002-20 | Sponsor Protocol Number: 2014METAL1 | Start Date*: 2015-06-10 |
Sponsor Name:UMCG | ||
Full Title: A multicentre randomized double-blind placebo controlled discontinuation trial of methylphenidate | ||
Medical condition: attention-deficit/hyperactivity disorder | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-001694-24 | Sponsor Protocol Number: D1050302 | Start Date*: 2014-03-11 | |||||||||||
Sponsor Name:SUNOVION PHARMACEUTICALS INC. | |||||||||||||
Full Title: A 104-WEEK, FLEXIBLE-DOSE, OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFECTIVENESS OF LURASIDONE IN PEDIATRIC SUBJECTS WITH SCHIZOPHRENIA AND SUBJECTS WITH IRRIT... | |||||||||||||
Medical condition: SCHIZOPHRENIA AND IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) IT (Prematurely Ended) BG (Completed) Outside EU/EEA HU (Completed) GB (Completed) DE (Completed) PL (Completed) BE (Completed) FR (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003651-54 | Sponsor Protocol Number: 2014RISP1 | Start Date*: 2015-10-14 |
Sponsor Name:UMCG | ||
Full Title: ‘Off-label use of Risperidone in Children and Adolescents (ORCA): a double-blind placebo-controlled discontinuation trial’ | ||
Medical condition: no specific condition, we will investigate children who have been using risperidone on an off-label basis for at least one year. | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-022647-38 | Sponsor Protocol Number: P06107 | Start Date*: 2011-11-16 | |||||||||||
Sponsor Name:Schering-Plough Research Institute, a Division of Schering Corporation | |||||||||||||
Full Title: Efficacy and Safety of 3-Week Fixed-Dose Asenapine Treatment in Pediatric Acute Manic or Mixed Episodes Associated with Bipolar I Disorder (Protocol No. P06107) | |||||||||||||
Medical condition: Acute Manic or Mixed Episodes Associated with Bipolar I Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003806-33 | Sponsor Protocol Number: AEGR-733-020 | Start Date*: 2016-06-30 | |||||||||||
Sponsor Name:Aegerion Pharmaceuticals Inc. | |||||||||||||
Full Title: A Phase 3, Single-arm, Open-label, International, Multi-center Study to Evaluate the Efficacy and Safety of Lomitapide in Pediatric Patients with Homozygous Familial Hypercholesterolemia on Stable ... | |||||||||||||
Medical condition: Homozygous familial hypercholesterolemia (HoFH). | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Not Authorised) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003008-38 | Sponsor Protocol Number: 105MS306 | Start Date*: 2019-06-17 | ||||||||||||||||
Sponsor Name:Biogen Idec Research Limited | ||||||||||||||||||
Full Title: An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years f... | ||||||||||||||||||
Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: CZ (Ongoing) FR (Ongoing) PT (Ongoing) HU (Ongoing) BE (Completed) SK (Ongoing) GR (Completed) DE (Completed) ES (Ongoing) HR (Ongoing) IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004160-38 | Sponsor Protocol Number: 93-8122-001 | Start Date*: 2015-04-01 |
Sponsor Name:KABI PHARMACIA S.A. | ||
Full Title: A 2 Year Multicenter Study of Genotropin Treatment of Short Prepubertal Children with Intra-Uterine Growth Retardation | ||
Medical condition: Growth Disorders, Intrauterine Growth Retardation | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2020-002187-31 | Sponsor Protocol Number: 03-08022022 | Start Date*: 2021-11-19 | |||||||||||
Sponsor Name:Department of Paediatrics, Herlev Hospital | |||||||||||||
Full Title: A parallel group, double-blinded randomised multi dose pharmacokinetic and safety study of melatonin in children and adolescents | |||||||||||||
Medical condition: Healthy children and adolescents | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000821-29 | Sponsor Protocol Number: SPD503-401 | Start Date*: 2020-11-19 | |||||||||||
Sponsor Name:Takeda Development Center Americas, Inc. | |||||||||||||
Full Title: A Phase 4, Multicenter, 2-part Study Composed of a 1-Year Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation followed by a 1-Year Open-lab... | |||||||||||||
Medical condition: Attention-deficit/hyperactivity disorder (ADHD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) NL (Trial now transitioned) SE (Trial now transitioned) AT (Prematurely Ended) ES (Ongoing) BE (Ongoing) PT (Prematurely Ended) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000387-14 | Sponsor Protocol Number: RM-493-014 | Start Date*: 2017-05-24 |
Sponsor Name:Rhythm Pharmaceuticals, Inc. | ||
Full Title: Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients with rare genetic disorders of obesity | ||
Medical condition: - POMC/PCSK1/LEPR heterozygous - POMC/PCSK1/LEPR compound heterozygous or homozygous deficiency obesity - POMC/PCSK1/LEPR composite heterozygous deficiency obesity - Smith-Magenis Syndrome - SH2B1... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) DE (Completed) FR (Ongoing) NL (Completed) GR (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-003265-36 | Sponsor Protocol Number: AG348-C-022 | Start Date*: 2022-05-10 | |||||||||||
Sponsor Name:Agios Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Subjects With Pyruvate Kinase Deficiency Who Are Regularly T... | |||||||||||||
Medical condition: Pyruvate Kinase Deficiency | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Ongoing) CZ (Ongoing) DK (Ongoing) IT (Prematurely Ended) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001855-15 | Sponsor Protocol Number: QBGJ398-203 | Start Date*: 2022-02-02 | |||||||||||
Sponsor Name:QED Therapeutics, Inc. | |||||||||||||
Full Title: Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children with Achondroplasia: PROPEL OLE | |||||||||||||
Medical condition: Achondroplasia in Children | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000751-42 | Sponsor Protocol Number: D1441C00150 | Start Date*: 2006-04-07 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A 26-week, International, Multicenter, Open-label Phase IIIb Study of the Safety and Tolerability of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets in Daily Doses of 400 mg to 800 mg in ... | ||
Medical condition: SCHIZOPHRENIA or BIPOLAR I DISORDER | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.